• Joylent.eu’s European Soylent clone was criticized for excessive vitamin A (325 000 IU/serving), cheap magnesium oxide, cyanocobalamin instead of methylcobalamin, and an unfavorable ω-6:ω-3 ratio; DIY micronutrient stacks were calculated to cost ~US $1/day versus Joylent’s €2/meal.

• CRISPR/Cas9 and zinc-finger nucleases are moving toward first-in-human trials: Toronto’s Ronald Cohn plans dystrophin correction in a 13-year-old Duchenne patient within three years, while Sangamo’s hemophilia B trial already shows functional factor IX expression; complementary papers detail exon excision, allele-specific knockout, and large-duplication removal strategies for DMD, achondroplasia, and MECP2 duplication syndromes.

• Thymic rejuvenation research in mice demonstrates that either transplantation of young thymic epithelial cells or single-gene up-regulation of FOXN1 restores naive T-cell output, offering two concrete routes to reverse age-related immune decline and preserve T-cell clonal diversity in humans.

• Reusable Falcon 9 first-stage landings could drop marginal launch costs from ~US $60 M to US $100 k–1 M if aircraft-level maintenance cycles are achieved, potentially transforming access-to-space economics.

• Ultra-high-vacuum DIY progress: backpack-sized turbo pumps (Creare/NASA MiniVac, $8 k, 36–60 L/min) reach 7×10⁻⁵ mbar in ~160 s for 1 L chambers—adequate for basic SEM and borderline mass-spec work—while open questions remain about scaling very small pumps to very large chambers.

• Intermittent-fasting biochemistry debates center on autophagy, Nrf2, AMPK, and ketosis versus stress-induced cortisol/gluconeogenesis that can erode lean mass; 19-hour daily fasts reportedly boost late-day energy after a two-month adaptation period.

• Alternative pharma-financing models discussed include abolishing drug patents in favor of Health Impact Fund pull incentives, Andy Lo’s digital-put options and FDA swaps to hedge pipeline risk, and dynamic-leverage securitization for pre-clinical drug portfolios lacking steady cash flows.

• A proposal for anonymous peer review—arguing that removing author identity improves objectivity—was circulated, with participants noting the irony that the paper itself is not anonymous.